Depression and anxiety are common disorders in youth that can have profound influences on functioning and even mortality. In the late 1990s, large controlled trials began demonstrating the efficacy of selective serotonin reuptake inhibitors for these conditions in the pediatric population. By 2003, regulatory agencies began warning the public of unrecognized risk and misrepresented benefit. The current review article summarizes a series of published and unpublished efficacy and safety data regarding antidepressant use in children and adolescents. The resulting complex synthesis suggests that these medications may offer mild-to-moderate benefit, with notable exceptions depending on medication and indication, but they may also heighten the risk for suicidal ideation and parasuicidal behavior. However, reviewed epidemiological data does not demonstrate a relationship between newer antidepressant prescription and completed suicide in large populations of youth. In conclusion, this breadth of mixed research data is applied to clinical decision making.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Costello EJ, Egger HL, Angold A . Developmental epidemiology of anxiety disorders. In: Ollendick TH, March JS (eds). Phobic and Anxiety Disorders in Children and Adolescents. Oxford University Press: New York, 2004, pp 61–91.
Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrew JA . Adolescent psychopathology, I: prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993; 102: 133–144.
Lewinsohn PM, Clarke GN, Seeley JR, Rohde P . Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994; 33: 809–818.
Center for Disease Control and Prevention. Suicide trends among youths and young adults aged 10-24 years—United States, 1990-2004. Morb Mortal Wkly Rep 2007; 56: 905–908.
Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE et al. Childhood and adolescent depression: a review of the past ten years, Part I. J Am Acad Child Adolesc Psychiatry 1996; 35: 1427–1439.
Grunbaum JA, Kann L, Kinchen SA, Williams B, Ross JG, Lowry R et al. Youth risk behavior surveillance—United States, 2001. Morb Mortal Wkly Rep Surveill Summ 2002; 51: 1–62.
National Center for Injury Prevention and Control. WISQARS Leading Causes for Death Reports, 1999–2007. US Department of Health and Human Services, Center for Disease Control: GA, USA. Application last reviewed 1 June 2010, available at http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html. Accessed on 26 October 2011.
Eaton DK, Kann L, Kinchen SA, Shanklin S, Ross J, Hawkins J et al. Youth risk behavior surveillance—United States, 2007. Morb Mortal Wkly Rep Surveill Summ 2008; 57: 1–131.
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–1037.
Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205–1215.
Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033–1041.
March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al. Setraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280: 1752–1756.
Geller DA, Hoog SL, Heiligentein JH, Ricardi RK, Tamura R, Kluszynski S et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 773–779.
Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 222–229.
Duff G . Safety of Seroxat (Paroxetine) in children and adolescents under 18 years—Contraindication in the treatment of depressive illness. Medicines and Healthcare Products Regulatory Agency, UK Department of Health. 10 June 2003; available at http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019507.pdf. Accessed on 26 October 2011.
Medicines and Healthcare Products Regulatory Agency. Selective serotonin receptors: overview of regulatory status and CSM advice relating to major depressive disorder in children and adolescents including a summary of available safety and efficacy data UK Department of Health. 10 December 2003; available at http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON002045. Accessed on 26 October 2011.
United States Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressants US Department of Health and Human Services. 22 March 2004; available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161696.htm.Accessed on 8 August 2011.
United States Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications US Department of Health and Human Services. 15 October 2004; available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm. Accessed on 5 August 2011.
Harvey M . European Medicines Agency finalises review of antidepressants in children and adolescents European Medicines Agency. 25 April 2005; available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/12/news_detail_000882.jsp&mid=WC0b01ac058004d5cl&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true. Accessed on 26 October 2011.
Vlk J . Health Canada advises Canadians of stronger warnings for SSRIs and other newer antidepressants. Health Canada. 3 June 2004; available at http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2004/2004_31-eng.php. Accessed on 22 August 2011.
Adverse Drug Reactions Advisory Committee. Use of SSRI antidepressants in children and adolescents. Australian Government Department of Health and Ageing. 15 October 2004; available at http://www.tga.gov.au/safety/committees-adrac-ssri-041015.htm. Accessed on 15 August 2011.
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807–820.
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al. The Treatment for Adolescents with Depression Study (TADS) Long-term Effectiveness and Safety Outcomes. Arch Gen Psychiatry 2007; 64: 1132–1144.
Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE . A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161: 1079–1083.
Von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A . A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006; 26: 311–315.
Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher DJ et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–772.
Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong K, Carpenter DJ et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006; 45: 709–719.
Wagner KD, Jonas J, Findling R, Ventura D, Saikali K . A double-blind randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 280–288.
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression. The TORDIA randomized controlled trial. JAMA 2008; 299: 901–913.
Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial. JAMA 2004; 292: 1969–1976.
Geller DA, Wagner KD, Emslie GJ, Murphy T, Carpenter DJ, Wetherhold E et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43: 1387–1396.
Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344: 1279–1285.
Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42: 415–423.
Wagner KD, Berard R, Stein MG, Wetherhold E, Carpenter DJ, Perera P et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004; 61: 1153–1162.
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683–1696.
Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK et al. ACNP Task Force Report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31: 473–492.
Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boardington E et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–1345.
Hammad TA, Laughren T, Racoosin J . Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332–339.
Simeon JG, Dinicola VF, Ferguson HB, Copping W . Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 791–795.
Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C . An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006; 16: 59–75.
Emslie GJ, Findling RL, Rynn MA, Marcus RN, Fernandes LA, D'Amico MF et al. Efficacy and safety of nefazodone in the treatment of adolescents with major depressive disorder [abstract]. J Child Adolesc Psychopharmacol 2002; 12: 299.
US Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data US FDA. 2004; available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed 10 January 2005.
Dubitsky, GM . Review and evaluation of clinical data: placebo-controlled antidepressant studies in pediatric patients. US FDA. 6 August 2004; available at: http://www.fda.gov/OHRMS/DOCKETS/ac/04/briefing/2004-4065b1-08-TAB06-Dubitsky-Review.pdf. Accessed on 26 October 2011.
Cheung AH, Emslie GJ, Mayes TL . Review of the efficacy safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005; 46: 735–754.
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y . Venlafaxine ER for the treatment of pediatric subjects with depression: results of 2 placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 479–488.
Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1431–1438.
Rynn MA, Siqueland L, Rickels K . Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158: 2008–2014.
Rynn MA, Riddle MA, Yeung PP, Kunz NR . Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007; 164: 290–300.
Tourian KA, March JS, Mangano RM . Venlafaxine ER in children and adolescents with SAD. Paper presented at: 157th Annual Meeting of the American Psychiatric Association; 1–6 May 2004; New York, NY.
March JS, Entsuah AR, Rynn M, Albano AM, Tourian KA . A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 2007; 62: 1149–1154.
Gray D, Moskos M, Keller T . Utah Youth Suicide Study: new findings. Paper presented at: the proceedings of the 36th Annual Conference of the American Association of Suicidology; 22–26 April 2003; Santa Fe, NM.
Leon AC, Marzuk PM, Tardiff K, Teres JJ . Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004; 65: 915–918.
Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA . National trends in the outpatient treatment of depression. JAMA 2002; 287: 203–209.
Gibbons RD, Hur K, Bhaumik DK, Mann JJ . The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165–172.
Carlsten A, Waern M, Ekedahl A, Ranstam J . Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001; 10: 525–530.
Ohberg A, Vuori E, Klaukka T, Lonngvist J . Antidepressants and suicide mortality. J Affect Disord 1998; 50: 225–233.
Olfson M, Shaffer D, Marcus SC, Greenberg T . Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–982.
Hamilton BE, Minino AM, Martin JA, Kochanek KD, Strobino DM, Guyer B . Annual summary of vital statistics: 2005. Pediatrics 2007; 119: 345–360.
Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik VK, Erkens JA et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356–1363.
Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J . Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. Can Med Assoc J 2008; 178: 1005–1011.
The authors declare no conflict of interest.
About this article
Cite this article
Henry, A., Kisicki, M. & Varley, C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry 17, 1186–1193 (2012). https://doi.org/10.1038/mp.2011.150
Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD
European Child & Adolescent Psychiatry (2017)